What is the history of 1p36 Deletion Syndrome?

1p36 Deletion Syndrome was first clinically characterized in the 1980s as a distinct chromosomal disorder caused by the loss of genetic material from the end of the short arm of chromosome 1. While early reports focused on identifying the syndrome through physical features, modern genomic technologies like chromosomal microarray analysis have since redefined our understanding, allowing for precise mapping of the deleted segments and better correlation with specific clinical outcomes.

How was 1p36 Deletion Syndrome first identified?

In the late 1980s, researchers began to recognize a recurring pattern of developmental delay, intellectual disability, and characteristic facial features in patients who shared a common deletion on chromosome 1. Before this, these individuals were often misdiagnosed or categorized under broader developmental delay labels. The formal recognition of 1p36 Deletion Syndrome as a distinct clinical entity was made possible by the development of high-resolution cytogenetics, which allowed clinicians to visualize the specific terminal deletion that defines the condition.

How has our understanding of 1p36 Deletion Syndrome evolved?

The understanding of 1p36 Deletion Syndrome has shifted from a strictly clinical description to a genotype-phenotype correlation model. Advancements in molecular genetics have corrected early misconceptions, revealing that the size and location of the deletion can vary significantly between individuals. This variability explains the wide spectrum of symptoms, ranging from mild learning difficulties to severe medical complexities. Key milestones in this evolution include:

• 1990s: Use of Fluorescence In Situ Hybridization (FISH) to confirm the terminal 1p36 deletion.


• 2000s: The introduction of Array Comparative Genomic Hybridization (aCGH), which allowed for the detection of smaller, submicroscopic deletions.


• Ongoing: Current research focuses on "dosage-sensitive" genes within the 1p36 region that contribute to epilepsy, cardiac defects, and growth patterns.

How has patient advocacy shaped the history of this condition?

For many years, families of children with 1p36 Deletion Syndrome faced isolation due to the rarity of the diagnosis. The rise of digital advocacy has been a turning point, connecting families globally to share lived experiences. Today, communities like DiseaseMaps, which currently supports 22 members with 1p36 Deletion Syndrome, play a vital role in providing emotional support and gathering patient-reported data that complements clinical research.

Next steps

• Consult a medical geneticist to review the specific genomic coordinates of your 1p36 Deletion Syndrome diagnosis.


• Connect with the 1p36 Deletion Support & Awareness group for family resources.


• Register with DiseaseMaps.org to contribute to the growing body of patient-driven data.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): 1p36 deletion syndrome.


• Orphanet: Terminal deletion of the short arm of chromosome 1.


• Online Mendelian Inheritance in Man (OMIM): #607872, Chromosome 1p36 Deletion Syndrome.


• 1p36 Deletion Support & Awareness (1p36DSA) Foundation.